Human skin fibroblasts were isolated from a 48-year-old patient carrying compound heterozygous mutations (c.610+364GN A and c.1311AN G) in OPA1, responsible for early onset optic atrophy complicated by ataxia and pyramidal signs (Behr syndrome; OMIM #210000). Fibroblasts were reprogrammed using episomal plasmids carrying hOCT4, hSOX2, hKLF4, hL-MYC and hLIN28. The generated transgene-free line iPS-OPA1-BEHR showed no additional genomic aberrations, maintained the disease-relevant mutations, expressed important pluripotency markers and was capable to differentiate into cells of all three germ layers in vitro. The generated iPS-OPA1-BEHR line might be a useful platform to study the pathomechanism of early onset complicated optic atrophy syndromes.
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Resource details
In this study fibroblasts were isolated and reprogrammed from a 48-year-old female patient carrying compound heterozygous mutations (c.610 + 364G NA and c.1311A N G) in OPA1. The combination of a deep intronic mutation and a mutation in an intragenic modifier leads to a severe early-onset optic atrophy phenotype complicated by ataxia and pyramidal signs (Behr syndrome; OMIM #210000) (Bonifert et al., 2014 ) (Chao de la Barca et al., 2016) . The iPSC line iPS-OPA1-BEHR was established by nucleofection of episomal plasmids carrying the sequence of OCT4, SOX2, KLF4, L-MYC and LIN28 (Okita et al., 2011) . To prove genomic integrity upon reprogramming, whole-genome single nucleotide polymorphism (SNP) genotyping of original fibroblasts and the generated iPSC line iPS-OPA1-BEHR was performed (Fig. 1A) . Additionally both mutation-sites were resequenced (Fig. 1B) and genomic integration of episomal plasmids was excluded (Fig. 1C) . Pluripotency of generated iPS-OPA1-BEHR was analysed via alkaline phosphatase staining (ALP) ( Fig. 2A) , staining of pluripotency markers OCT4, TRA-1-81 and SSEA-4 ( Fig. 2B ), comparative qRT-PCR analysis of pluripotency markers (OCT4, NANOG, KLF4, C-MYC, SOX2, REX1, DNMT3B and TDGF1) with human embryonic stem cells and fibroblasts (Fig. 2C) as well as by the capability to differentiate into cells of all three germ layers (ectoderm, mesoderm, endoderm) ( 
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Materials and methods

Reprogramming of fibroblast to iPSCs
Fibroblasts were obtained from a skin biopsy of a 48-year-old female patient carrying compound heterozygous mutations (c.610+364GNA and c.1311A NG; NM: 130837.1) in OPA1. The patient suffered from optic atrophy and visual loss since the age of 2 years. At 6 years of age progressive gait difficulties occurred due to cerebellar ataxia, spasticity and peripheral neuropathy as described in more detail in Bonifert et al. (2014) . Skin tissue was dissected and directly plated in a 25 cm 2 tissue culture flask with Dulbecco's modified eagle's medium (DMEM) high glucose (Life Technologies) with 10% fetal bovine serum (FBS, Life Technologies) for 10 days at 37°C and 5% CO 2 . Fibroblasts were expanded by medium change every 2-3 days and reprogrammed by electroporation of 1 × 10 5 cells with a total of 1 μg per episomal plasmid (pCXLE-hUL, pCXLE-hSK and pCXLE-hOCT4) (Okita et al., 2011) . After electroporation fibroblasts were cultivated for 1 day in fibroblast medium. On day 2 fibroblast growth factor-2 (FGF-2, 2 ng/ml, Peprotech) was added to the medium followed by medium change to Essential 8 (E8) supplemented with 100 μM NaB (Sigma Aldrich) on day 3. Medium change was performed every other day. iPSC colonies were manually picked approx. 3-4 weeks after electroporation and expanded on Matrigel-coated dishes in E8 medium. iPSCs were split by adding PBS/ EDTA (0.02% EDTA in PBS) and replated in a ratio of 1:6-1:12. Around passage 5-10 iPSCs were genomically and functionally analysed and frozen in E8 medium supplemented with 40% KOSR (Life Technologies), 10% DMSO (Sigma-Aldrich), and 1 μM Y-27632 (Abcam Biochemicals).
SNP array analysis
DNA of iPSCs was isolated with DNeasy Blood and Tissue Kit (Qiagen) according to manufacturer's instructions. Whole-genome SNP genotyping was conducted using the Infinium OmniExpressExome-8 BeadChip (Illumina). Data analysis was performed with Illumina BeadStudio.
Sequencing of mutation site
DNA from the patient's fibroblasts and iPSCs was extracted using the DNeasy blood & tissue kit (Qiagen) according to manufacturer's guidelines. Subsequently, Sanger sequencing of both mutations (c.610 + 364G NA and c.1311A N G) in OPA1 was carried out using specific primer sets flanking the mutation sites according to standard procedures by using 3130xl Genetic Analyzer (Applied Biosystems) and Staden 2.0.0b10 software (Staden Sourceforge) for visualisation.
Non-integration of transgenes
DNA was isolated as described before. Using the GoTaq G2 DNA Polymerase (Promega) according to manufacturer's instruction as well as plasmid-specific primers (see Table 1 ) genomic integration of the episomal plasmids (pCXLE-hUL, pCXLE-hSK and pCXLEhOCT4) was excluded. Via gel electrophoresis on a 2% agarose gel with Midori Green and Gene Ruler DNA Ladder PCR products were analysed.
Alkaline phosphatase staining
IPSCs were fixed in 4% paraformaldehyde (PFA) for 1 min and washed 3 times with PBS after reaching a confluency of approx. 60-80%. Staining solution (40 μl Naphthol AS-MX phosphate alkaline KLF4  CCACCTCGCCTTACACATGAAG  TAGCGTAAAAGGAGCAACATAG  L-MYC  GGCTGAGAAGAGGATGGCTAC  TTTGTTTGACAGGAGCGACAAT  OCT3/4  CATTCAAACTGAGGTAAGGG  TAGCGTAAAAGGAGCAACATAG  SOX2 TTCACATGTCCCAGCACTACCAG TTTGTTTGACAGGAGCGACAAT solution (Sigma-Aldrich) and 1 ml Fast Red (1 mg/ml, Sigma Aldrich)) was applied for 30 min leading to dark red staining of ALP-positive iPSC colonies.
Immunocytochemical staining iPSCs as well as differentiated cells were fixed in 4% PFA for 15 min and washed 3 times with PBS. Subsequently, blocking solution (PBS supplemented with 1% FBS and 0.1% Triton X-100) was added for 45 min and samples were incubated with primary antibody (see Table 3 ) for 1 h at room temperature (RT). After 3 times washing in PBS secondary antibody (Alexa488 or Alexa568 diluted 1:300 (Life Technologies)) was applied and incubated for 1 h at RT in the dark. Nuclear counterstaining was achieved by adding DAPI (1:10,000) for 15 min at RT. After embedding cells in ProLong Diamond Antifade Mountant (Life Technologies) images were taken with Axio Imager Z1 with ApoTome (Zeiss).
qRT-PCR of pluripotency marker cDNA generated by using the Transcriptor High Fidelity cDNA Synthesis Kit (Roche) as well as prior isolated total RNA (High Pure RNA Isolation Kit (Roche)) according to manufacturer's guidelines was used for qRT-PCR analysis. qRT-PCR was performed as triplicates with Light Cycler 480 SYBR Green I Master (Roche) and primers specific for pluripotency genes (see Table 2 ). Normalization of C T -values was achieved by using the 2 − ΔΔCt method with the human embryonic stem cell line HuES-H6 as reference and GAPDH as housekeeping gene.
In vitro differentiation potential
For proving the ectodermal and mesodermal differentiation potential iPSCs were detached and resuspended in Embryoid Body (EB) medium (80% DMEM/F12 (Life Technologies), 20% KOSR, 1× NEAA, 1× Pen/ Strep, 2 mM L-Glutamine and 0.1 mM 2-Mercaptoethanol) on AggreWell 800 plates (Stemcell Technologies) with medium change at day 2. EBs were collected and plated on 0.1% gelatine-covered wells (Sigma-Aldrich) at day 4. EB medium was exchanged every other day and cells were cultivated for additional 2-3 weeks. Endodermal differentiation of iPSCs was achieved by addition of endodermal differentiation medium (RPMI1640 (Merck) supplemented with 1 × B27 (Life Technologies), 0.2% FBS, 2 μM CHIR-99021 (Abcam) and 50 ng/ml Activin A (Peprotech)) for 5 days. CHIR-99021 was removed from day 2 on and medium was changed every day. ATTCTCTGCTCTCCTCGACG  CTGTGAGGAGGTTTGCTGTG  DNMT3  ACGACACAGAGGACACACAT  AAGCCCTTGATCTTTCCCCA  GAPDH  AGGTCGGAGTCAACGGATTT  ATCTCGCTCCTGGAAGATGG  KLF4  CCATCTTTCTCCACGTTCGC  CGTTGAACTCCTCGGTCTCT  NANOG  CAAAGGCAAACAACCCACTT  TGCGTCACACCATTGCTATT  OCT4  GGAAGGTATTCAGCCAAACG  CTCCAGGTTGCCTCTCACTC  REX1  AACGGGCAAAGACAAGACAC  AACTCACCCCTTATGACGCA  SOX2  TGATGGAGACGGAGCTGAAG  GCTTGCTGATCTCCGAGTTG  TDGF1 GGTCTGTGCCCCATGACA AGTTCTGGAGTCCTGGAAGC 
